All publications

Formulation Components' Role in Shaping Continuous Nanocarrier Production through Impingement Jet Mixing

  • Poster

PBP - Mar 2024

C. Tetyczka, M. Zettl, C. Glader, R. Jeitler, S. Stephan, M. Segl, Y. Wang, P. Caisse, V. Bourgeaux, M. Spoerk, J. Khinast, E. Roblegg

Flash nanoemulsification with impingement jet mixing is a technique used to produce nanocarriers. This study optimized the nanocarrier formulation to facilitate the manufacturing process and monitoring.

Implementation of an at-line nanoparticle size analyzer in a continuous nano-manufacturing line considering critical measurement and process conditions

  • Poster

PBP - Mar 2024

C. Glader, R. Jeitler, N. Cacic, Y. Wang, C. Tetyczka, M. Zettl, J. Khinast, M. Rossano, S. Mesite, M. Lübbert, E. Roblegg

Nanopharmaceuticals' size is a critical quality attribute. This work provides insights about the implementation of an at-line particle size analyzer in a continuous manufacturing line of solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC).

Establishment of a continuous inline-monitored nano-production line using the Microfluidizer® technology for the fabrication of safe lipid-based nanoparticles

  • Scientific publication

Macedonian Pharmaceutical Bulletin - Sep 2023

Christina Glader, Ramona Jeitler, Yan Wang, Carolin Tetyczka, Manuel Zettl, Johannes Khinast, Manon Rossano, Steve Mesite, Matthias Lübbert, Eva Roblegg

Nano-drug delivery systems (NDDS) serve as a promising platform in modern medicine, facilitating the targeted delivery of drugs due to their versatile size, structure, and composition. However, the current industrial production of NDDS relies on cumbersome batch processes that are costly, difficult to scale, and lack adequate control. This study focuses on enhancing industrial-scale production through the development and testing of a continuous top-down production line, utilizing scalable Microfluidizer® technology for solvent-free preparation of lipid-based nanoparticles.

In vivo confirmation of the permeation enhancement capacity of Labrafac™ MC60

  • Poster

AAPS PharmSci360 – Orlando (USA) - Oct 2023

Fiona McCartney, Philippe Caisse , Camille Dumont, David J. Brayden

Self-emulsifying drug delivery systems (SEDDS): In vivo-proof of concept for oral delivery of insulin glargine

  • Scientific publication

International Journal of Pharmaceutics 639 - 122964 - May 2023

Victor Claus , Helen Spleis, Christoph Federer, Katrin Z ̈oller, Richard Wibel, Flavia Laffleur, Camille Dumont, Philippe Caisse, Andreas Bernkop-Schnürch

In this study, lipophilicity of insulin glargine (IG) was successfully increased via hydrophobic ion pairing (HIP) with sodium octadecyl sulfate to enable incorporation into self-emulsifying drug delivery systems (SEDDS). The SEDDS formulations F1 and F2 were administered to rats via oral gavage and resulted in a bioavailability of 0.55% and 0.44%, corresponding to a 7.7-fold and 6.2-fold increased bioavailability, respectively. Thus, incorporation of complexed insulin glargine into SEDDS formulations provides a promising approach to facilitate its oral absorption.

LIPID-BASED EXCIPIENTS – Misconceptions About Lipid-Based Drug Delivery

  • Whitepaper

Drug Development & Delivery - Apr 2023

Rollie Fuller and Ron Permutt

An All-Purpose Vehicle for Low-Energy Capsule Filling

  • Whitepaper

Tablets&Capsules - Apr 2023

Jasmine Musakhanian; Masumi Dave; Elise Dauphin-Chanard

Capsules are perceived as elegant, easy-to-swallow dosage forms, widely used for delivery of nutraceutical and medicinal preparations. Advances in capsule technologies have hugely facilitated the incorporation of liquid, semi-solid, and solid ingredients into capsules. 

A Systematic Approach to Developing Lipid-Based Drug Delivery Systems with Fenofibrate as Model Drug

  • Poster

AAPS PharmSci360 – Boston (USA)  - Oct 2022

Masumi Dave, Reena Rahi and Jasmine Musakhanian

Impact of Granulation Solvent on Release Performance of Dual Matrix Extended-Release Tablets of Highly Water Soluble Drugs Formulated using Compritol® 888 ATO and Methocel® as Release Retarding Agents

  • Poster

AAPS PharmSci360 – Boston (USA)  - Oct 2022

Ketkee Deshmukh, Swarnadeep Banerjee, Agnivesh Shrivastava, Sunil Bambarkar

The purpose of this study is to evaluate the impact of different granulation solvents on the performance of dual extended- release matrix tablets, formulated using a combination of Compritol® 888 ATO and Methocel® K100M, with two model APIs:

- highly water-soluble high dose (1000 mg) Metformin Hydrochloride

- freely water-soluble low dose (95 mg) Metoprolol Succinate